11/11/2011

Watson Pharmaceuticals secured FDA approval for extended-release morphine sulfate, a generic version of Actavis Group's painkiller Kadian. Separately, Watson was sued by Novartis in connection with the former's FDA application to market a generic version of Exelon, the latter's drug patch for dementia.

Related Summaries